Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x)
Articolo
Data di Pubblicazione:
2022
Abstract:
Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5. The original article has been corrected.
Tipologia CRIS:
1.1.5. Erratum
Elenco autori:
Barbanti, P.; Egeo, G.; Aurilia, C.; D'Onofrio, F.; Albanese, M.; Cetta, I.; Di Fiore, P.; Zucco, M.; Filippi, M.; Bono, F.; Altamura, C.; Proietti, S.; Bonassi, S.; Vernieri, F.
Link alla scheda completa:
Pubblicato in: